Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting.

Gong, Xubo; He, Xin; Wang, Lin; Yu, Teng; Liu, Weiwei; Xu, Huiying; Jin, Lan; Li, Xiang; Zhang, Bin; Tao, Zhihua; Qian, Wenbin

Gong, Xubo; He, Xin; Wang, Lin; Yu, Teng; Liu, Weiwei; Xu, Huiying; Jin, Lan; Li, Xiang; Zhang, Bin; Tao, Zhihua; Qian, Wenbin.

Afiliación

Gong X; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
He X; Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Wang L; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
Yu T; Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China.
Liu W; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
Xu H; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
Jin L; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
Li X; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
Zhang B; Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA. bzhang@coh.org.
Tao Z; Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China. zrtzh@zju.edu.cn.
Qian W; Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China. qianwb@zju.edu.cn.

Exp Hematol Oncol ; 13(1): 17, 2024 Feb 16.

Article en En | MEDLINE | ID: mdl-38365742

ABSTRACT

ABSTRACT

Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been established as the standard treatment for elderly or medically unfit AML patients unable to undergo intensive chemotherapy. Despite this, the availability of novel VEN-based therapies specifically tailored for those with R/R AML remains scarce. Here, we provide a comprehensive overview of the latest data presented at the 65th American Society of Hematology Annual Meeting, shedding light on the progress and efficacy of VEN-based therapies for R/R AML.

Palabras clave

Acute myeloid leukemia; Hypomethylating agents; Venetoclax

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2024 Tipo del documento: Article